CN113853205A - 表达FCγ受体的T细胞及其使用方法 - Google Patents

表达FCγ受体的T细胞及其使用方法 Download PDF

Info

Publication number
CN113853205A
CN113853205A CN202080037294.9A CN202080037294A CN113853205A CN 113853205 A CN113853205 A CN 113853205A CN 202080037294 A CN202080037294 A CN 202080037294A CN 113853205 A CN113853205 A CN 113853205A
Authority
CN
China
Prior art keywords
cell
leu
ser
cells
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080037294.9A
Other languages
English (en)
Chinese (zh)
Inventor
亚龙·卡米
皮勒·里德
戴安娜·拉苏鲁尼里亚娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CN113853205A publication Critical patent/CN113853205A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN202080037294.9A 2019-03-19 2020-03-19 表达FCγ受体的T细胞及其使用方法 Pending CN113853205A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820357P 2019-03-19 2019-03-19
US62/820,357 2019-03-19
PCT/IL2020/050327 WO2020188570A1 (en) 2019-03-19 2020-03-19 T cell expressing an fc gamma receptor and methods of use thereof

Publications (1)

Publication Number Publication Date
CN113853205A true CN113853205A (zh) 2021-12-28

Family

ID=72519182

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080037294.9A Pending CN113853205A (zh) 2019-03-19 2020-03-19 表达FCγ受体的T细胞及其使用方法

Country Status (8)

Country Link
US (2) US20210401893A1 (enExample)
EP (1) EP3941492A4 (enExample)
JP (1) JP2022525927A (enExample)
CN (1) CN113853205A (enExample)
AU (1) AU2020243623A1 (enExample)
CA (1) CA3133037A1 (enExample)
IL (1) IL286477A (enExample)
WO (1) WO2020188570A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117660500A (zh) * 2023-09-28 2024-03-08 上海恩凯细胞技术有限公司 核酸构建体、载体、转基因免疫细胞及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021260696A1 (en) 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
WO2024236557A1 (en) 2023-05-12 2024-11-21 Gilboa Therapeutics LTD Compositions comprising an fc domain for the treatment of medical conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023148A2 (en) * 2004-07-10 2006-03-02 Fox Chase Cancer Center Genetically modified human natural killer cell lines
WO2016149109A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Universal antibody-mediated biosensor
US20170151283A1 (en) * 2014-05-23 2017-06-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
CN107580628A (zh) * 2014-09-17 2018-01-12 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
WO2016040441A1 (en) * 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023148A2 (en) * 2004-07-10 2006-03-02 Fox Chase Cancer Center Genetically modified human natural killer cell lines
US20170151283A1 (en) * 2014-05-23 2017-06-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
CN107580628A (zh) * 2014-09-17 2018-01-12 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
WO2016149109A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Universal antibody-mediated biosensor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATARZYNA URBANSKA等: "Overcoming Resistance To Antibody Targeted Therapy in Cancer Using Gene-Modifi ed T Cells", MOLECULAR THERAPY VOLUME, vol. 22, pages 297 - 298 *
SANDEEP KRISHNAN 等: "The FcRγ Subunit and Syk Kinase Replace the CD3ζ-Chain and ZAP-70 Kinase in the TCR Signaling Complex of Human Effector CD4 T Cells", 《THE JOURNAL OF IMMUNOLOGY》, vol. 170, no. 8, 15 April 2003 (2003-04-15), pages 4189 - 4195 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117660500A (zh) * 2023-09-28 2024-03-08 上海恩凯细胞技术有限公司 核酸构建体、载体、转基因免疫细胞及其应用

Also Published As

Publication number Publication date
CA3133037A1 (en) 2020-09-24
IL286477A (en) 2021-10-31
WO2020188570A1 (en) 2020-09-24
AU2020243623A1 (en) 2021-11-04
EP3941492A1 (en) 2022-01-26
JP2022525927A (ja) 2022-05-20
US20210401893A1 (en) 2021-12-30
EP3941492A4 (en) 2023-05-03
US20250163128A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
ES2875959T3 (es) Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
CN108018299B (zh) 靶向bcma的嵌合抗原受体及其用途
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
WO2018006882A1 (zh) 抗密蛋白18a2的抗体及其应用
EP3858991A1 (en) Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
US20250163128A1 (en) T cell expressing an fc gamma receptor and methods of use thereof
KR20140127816A (ko) 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
US12077569B2 (en) Multi subunit protein modules, cells expressing same and uses thereof
BR112019017008A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, imunoconjugado multifuncional, receptor de antígeno quimérico, vírus, célula imune modificada pelo receptor do antígeno quimérico, composição farmacêutica, kit, e, uso do anticorpo.
WO2020118634A1 (zh) 靶向gpc3的免疫效应细胞及其应用
CN108395478A (zh) 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
US12570714B2 (en) Siglec-based chimeric polypeptides and uses thereof
US20240335537A1 (en) Engineered soluble decoy receptors to enhance cancer immunotherapy
JP7057975B2 (ja) 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球
CN108864276B (zh) 靶向ny-eso-1的t细胞受体联合表达pd1抗体可变区及其用途
WO2018148180A2 (en) Materials and methods for identifying and treating cancer patients
JP2025523003A (ja) Ｖｃｙ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
WO2024243807A1 (zh) 靶向ny-eso-1的高亲和力t细胞受体及其应用
JP2024526836A (ja) Ｆａｎｃｉ、ｒａｄ５１、およびｐｂｋ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
WO2023242343A1 (en) Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
JP2024538169A (ja) Ｎｄｃ８０抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211228

WD01 Invention patent application deemed withdrawn after publication